Michael Fradley, Associate Chief of Outpatient Services, Cardiovascular Medicine at Penn Medicine, University of Pennsylvania Health System, shared a post on LinkedIn:
“Thank you to Medtronic for supporting ESC Cardio-Oncology 2026. It was a pleasure to moderate the session on rhythm monitoring with ILR in patients with cancer.
Congrats Robert Copeland-Halperin on your excellent work. And please check out our Archer study -off the press in JACC: CardioOncology.
First prospective ILR study in cancer population. In patients with new onset AFib during stem cell transplant:
- recurrence of afib at 2 yrs: 65%
- median time to recurrence: 3 months
- no device related complications.”
More posts featuring Michael Fradley.
